Development of a proteomic signature associated with severe disease for patients with COVID-19 using data from 5 multicenter, randomized, controlled, and prospective studies

Significant progress has been made in preventing severe COVID-19 disease through the development of vaccines. However, we still lack a validated baseline predictive biologic signature for the development of more severe disease in both outpatients and inpatients infected with SARS-CoV-2. The objectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro-Pearson, Sandra, Samorodnitsky, Sarah, Yang, Kaifeng, Lotfi-Emran, Sahar, Ingraham, Nicholas E., Bramante, Carolyn, Jones, Emma K., Greising, Sarah, Yu, Meng, Steffen, Brian, Svensson, Julia, Åhlberg, Eric, Österberg, Björn, Wacker, David, Guan, Weihua, Puskarich, Michael, Smed-Sörensen, Anna, Lusczek, Elizabeth, Safo, Sandra E., Tignanelli, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661735/
https://www.ncbi.nlm.nih.gov/pubmed/37985892
http://dx.doi.org/10.1038/s41598-023-46343-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661735/
https://www.ncbi.nlm.nih.gov/pubmed/37985892
http://dx.doi.org/10.1038/s41598-023-46343-1

Ejemplares similares